Nurix Therapeutics (NRIX) reported its Q3 2026 financial results after market close on July 9, 2026. The company reported an EPS of -0.81 USD, missing the analyst estimate of -0.72 USD by 12.1%. Revenue for the quarter was 9 million USD. Following the release, the stock price fell by 6.60%.
Generated automatically from our data — as of July 14, 2026
Key figures at a glance
Estimate (EPS): -0.72 USD
Reported (EPS): -0.81 USD
Price reaction: -6.6%
Frequently asked questions
Did Nurix Therapeutics beat or miss earnings-per-share expectations?
Nurix Therapeutics missed the analyst estimate of -0.72 USD earnings per share (Q2 2026) by 12.1%, reporting only -0.81 USD.
How did Nurix Therapeutics stock react to the earnings report?
Nurix Therapeutics stock fell 6.6% on the trading day following the release.
What was Nurix Therapeutics's revenue in Q2 2026?
Nurix Therapeutics reported revenue of 9M USD in Q2 2026.